The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022
The US anticoagulation therapy market is projected to reach USD 27.83 ...Read more
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%. The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics. The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs). On the other hand, the high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market. In addition, the growth in the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.
Download PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=114158575
